Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)
20 Juin 2023 - 2:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
to
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June 2023
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
EXPLANATORY NOTE
Purple Biotech Ltd. (the
“Company” or the “Registrant”) is filing this Amendment No. 1 to amend its Report on Form 6-K furnished
with the U.S. Securities and Exchange Commission (the “SEC”) on June 15, 2023 (the “Original Report”).
On June 15, 2023, the Company announced the results of the Annual General Meeting of Shareholders of the Company held on June 15, 2023.
This Amendment No. 1 is being filed solely for the purpose of updating the “Incorporation by Reference” disclosure included
in the Original Report, which inadvertently omitted to incorporate by reference into the Original Report the Registrant’s Registration
Statement on Form F-3, as amended, originally filed with the SEC on December 8, 2022 (Registration file number 333-268710). Other than
as expressly set forth above, this Amendment No. 1 does not, and does not purport to, amend, restate, or update the information contained
in the Original Report, or reflect any events that have occurred after the Original Report was filed.
Incorporation by Reference
This Report on Form
6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478),
the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6,
2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended,
originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the
Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019
(Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities
and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement
on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327),
[the Registrant’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission on December
27, 2019 (Registration file number 333-235729),] the Registrant’s Registration Statement on Form F-3 filed with the
Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number
333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange
Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement
on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107), the
Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023
(Registration file number 333-270769) and the Registrant’s Registration Statement on Form F-3, as amended,
originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or
furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
June 20, 2023 |
PURPLE BIOTECH LTD. |
|
|
|
|
By: |
/s/ Lior Fhima |
|
|
Lior Fhima |
|
|
Chief Financial Officer |
2
Purple Biotech (NASDAQ:PPBT)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Purple Biotech (NASDAQ:PPBT)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024